Pfizer Takes $491 Million Charge for Rapamune False Claims Act Settlement

Pfizer disclosed today that it has taken a $491 million charge to settle the Rapamune False Claims Act case against it.

The company said it has a deal with the Justice Department to settle “Wyeth’s historical promotional practices in connection with Rapamune.”

Rapamune is an organ transplant drug.

Pfizer acquired Wyeth in 2009.

The qui tam lawsuit was filed by Marlene Sandler and Scott Paris – two former employees at Wyeth.

Sandler and Paris are being represented by John Kairis, Traci Goins and Allessandra Phillilps of Grant & Eisenhofer in Wilmington, Delaware.

The lawsuit alleges that Wyeth engaged in illegal off-label marketing of Rapamune.

Copyright © Corporate Crime Reporter
In Print 48 Weeks A Year

Built on Notes Blog Core
Powered by WordPress